| Drug Name |
Plerixafor octahydrochloride |
| Drug ID |
BADD_D01789 |
| Description |
Plerixafor is a hematopoietic stem cell mobilizer. It is used to stimulate the release of stem cells from the bone marrow into the blood in patients with non-Hodgkin lymphoma and multiple myeloma for the purpose of stimulating the immune system. These stem cells are then collected and used in autologous stem cell transplantation to replace blood-forming cells that were destroyed by chemotherapy. Plerixafor has orphan drug status in the United States and European Union; it was approved by the U.S. Food and Drug Administration on December 15, 2008. |
| Indications and Usage |
Used in combination with granulocyte-colony stimulating factor (G-CSF, filgrastim) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM). |
| Marketing Status |
Prescription |
| ATC Code |
L03AX16 |
| DrugBank ID |
DB06809
|
| KEGG ID |
D08971
|
| MeSH ID |
C088327
|
| PubChem ID |
65014
|
| TTD Drug ID |
D0L5RW
|
| NDC Product Code |
55111-954; 71924-0063; 54893-0050; 0024-5862; 42973-202; 68554-0067; 76055-0017 |
| Synonyms |
plerixafor | 1,1'-(1,4-phenylenebis-(methylene))-bis-1,4,8,11-tetraazacyclotetradecane | plerixafor octahydrochloride | mezobil | mozobil | JM3100 | JM 3100 | AMD 3100 | AMD-3100 | AMD3100 | plerixafor hydrochloride | RPA bicyclam | AMD 3329 | AMD-3329 | plerixafor octahydrobromide | 1,1'-(1,4-phenylenebis-(methylene))-bis-1,4,8,11-tetraazacyclotetradecane octahydrochloride dihydrate | 1,1'-(1,4-phenylenebis(methylene))bis(1,4,8,11-tetraazacyclotetradecane)octahydrochloride dihydrate |
